National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The objective of this study was to determine the factors influencing low-level residual replication in patients infected with HIV-1 treated with TLD followed at the Center Polyvalent AL-Nadjma in N’Djamena, Chad. This was a retrospective and prospective study with an analytical aim which took place at the Polyvalent Al-Nadjma center from April 2022 to December 2023 in the city of N’Djamena. The study began with the interview of 135 patients, 108 of whom signed informed consent to participate in this study. Patients infected with HIV 1 on ART based on the combination of Tenofovir, Lamivudine and Dolutegravir (TLD) for at least 2 years with a load of 999 copies/mL were included. A total of 108 plasmas were collected and analyzed by the RT-PCR technique. The data from the interviews as well as the RT-PCR results were analyzed with R Studio software. 70% (76/108) of the participants were female with a M/F sex ratio of 0.42. The average age of the patients was 40.58 ± 9.58 years. Factors influencing residual replication were related to age with a prevalence of 27.27% of patients in the age group of 40 to 50 years, to initial HIV VL with 18.66% in patients who had an initial VL between 40 – 200 copies/ml and 22.22% in those with a baseline VL between 501 - 999 copies/ml, at prior ART, most patients were on prior ART consisting of (Viraday®). A prevalence of 23.95% of low-level residual viremia was observed in these patients and also non-compliance with a prevalence of 7.40% of residual viremia. Thus, it was found that factors influencing residual replication were linked to a higher risk of virological failure and poor immune reconstitution. A better understanding of the influencing factors and adverse effects in various states of residual viremia is expected to provide important guidance for HIV treatment.
Antiretroviral Therapy Cohort Collaboration, 2008. Life expectancy of individuals on combined antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. 2008. Lancet. 372; 293–299. https://doi.org/10.1016/S0140-6736(08)61113-7.
Bennett D E, Bertagnolio S, Sutherland D et al., 2008. The World Health Organization's global strategy for the prevention and assessment of HIV drug resistance. Antivir Ther 13(Suppl.2),1–13. https://doi.org/10.1177/135965350801302S03
Bijker R, Jiamsakul A, Kityo C et al., 2017. Adherence to antiretroviral treatment for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts. J.Int AIDS Soc. https://doi.org/10.7448/IAS.20.1.21218
Biocentric. 2019a. Analytical procedure for extraction of nucleic acids with the GXT-NA kit. ©-Toolkit-OP-ERA. 13pp
Biocentric. 2019b. Analytical procedure for amplification of HIV-1 nucleic acids with the GENERIC HIV viral load kit. ©-Toolkit-OP-ERA. 9pp.
CFDCA, Prevention CFDCA announcement followed by certain national HIV prevention and care objectives. 2017. MMWR Morbidity and Mortality Weekly Report. 66 (29):794. http://dx.doi.org/10.15585/mmwr.mm6629a6
Crowell T A, Pinyakorn S, Sacdalan C et al., 2020. RV254/SEARCH010 Study Group. Viral Blips After Treatment Initiation During Acute Human Immunodeficiency Virus Infection. Clin Infect Dis 70(12):2706–2709. https://doi.org/10.1093/cid/ciz936
D’Arminio Monforte A, Lepri A C, Rezza G, et al., 2000. Insights into the reasons fordis continuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS.;14(5):499–507. https://doi.org/10.1097/00002030-200003310-00005
Deeks S G, Walker B D. 2007. Human immunodeficiency virus controllers mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 27(3): 406-416. https://doi.org/10.1016/j.immuni.2007.08.010
Denardo D, Mojola S A, Schatz E et al., 2022. Antiretroviral therapy and aging as resources to manage and resist HIV stigma in rural South Africa. SSM Qual Res Health. 2:100148.33. https://doi.org/10.1016/j.ssmqr.2022.100148
Dinoso J B, Kim S Y, Wiegand A M et al., 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. J.M. Coffin. 106, 9403–9408. https://doi.org/10.1073/pnas.0903107106
Doyle T, Smith C, Vitiello P et al., 2012. Detection of plasma HIV-1 RNA below 50 copies/ml and risk of virological rebound in patients receiving highly active antiretroviral treatment. Clin Infect Dis. 54(5): 724-732. https://doi.org/10.1093/cid/cir936
Dybul M., Fauci A S, Bartlett J G et al., 2002. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med. 137 (5 part 2), 381-433. https://doi.org/10.7326/0003-4819-137-5_part_2-200209031-00001.
Elvstam O, Marrone G, Medstrand P, et al., 2021. All-cause mortality and non-AIDS-related serious events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish national observational study. Clin Infect Dis. 72, 2079-2086. https://doi.org/10.1093/cid/ciaa413
Elvstam O, Medstrand P, Yilmaz A et al., 2017. “Virologic failure and all-cause mortality in HIV-positive adults with low viremia during antiretroviral therapy.” PLoS Un. 12, 0180761. https://doi.org/10.1371/journal.pone.0180761
Esber A, Polyak C, Kiweewa F. et al., 2019. Persistent low-level viremia predicts subsequent virological failure: is it time to change the third 90? Clin Infect Dis. 69(5), 805-812 https://doi.org/10.1093/cid/ciy989
Hamelaar J, Gouws E, Ghys P D et al., 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 20(16): 13-23 https://doi.org/10.1097/01.aids.0000247564.73009.bc
Hsu J Y, Sun H Y, Hsieh T W et al., 2022. Incidence of low-level viremia and its impact on virological failure in people living with HIV-1 who are switched to elvitegravir-based antiretroviral therapy. Antimicrobial resistance J Glob. 29, 7-16. https://doi.org/10.1016/j.jgar.2022.02.007
Joya C, Won S H, Schofield C et al., 2019. Persistent low-level viremia during antiretroviral therapy is an independent risk factor for virological failure. Clin Infect Dis. 69(6), 2145-2152. https://doi.org/10.1093/cid/ciz129.
Kao S W, Liu Z H, Wu T S et al., 2021. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viremia on combination antiretroviral therapy: an observational study in a tertiary hospital in northern Taiwan from 2017-2019. J Antimicrobial chemotherapy. 76 (3), 722-728 https://doi.org/10.1093/jac/dkaa510.
Kiweewa F, Esber A, Musingye E, et al., 2019. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS One. 14(2). https://doi.org/10.1371/journal.pone.0211344
Lesko C R, Chander G., Moore R D et al., 2020. Variation in estimated viral suppression associated with the definition of viral suppression used. AIDS. 34, 1519-1526. https://doi.org/10.1097/QAD.0000000000002579
Ludo lavreys, Jared M B, Varsa C et al., 2006. Higher set-point plasma viral load and more severe acute HIV type 1 (HIV1) predict mortality in high-risk HIV-1-infected African women. Clinical infectious diseases. 42(9), 1333-1339. https://doi.org/10.1086/503258
Maldarelli F, Palmer S, King M S et al., 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3.46. https://doi.org/10.1371/journal.ppat.0030046
Mills E J, Nachega J B, Bangsberg D R, et al., 2006. Adherence to HAART, a systematic review of barriers and facilitators reported by patients in developed and developing countries. Plos Med. 3:438. https://doi.org/10.1371/journal.pmed.0030438
Palella F J J R, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, et al., (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Out patient Study Investigators. NEngl JMed. 338, 853–860. https://doi.org/10.1056/NEJM199803263381301
Rello A P, Aznarez H N, Martinez A M, et al., 2022. Study of factors that influence low-level viremia in human immunodeficiency virus patients in a tertiary hospital. Infect Dis Clin Pract. 30(1). https://doi.org/10.1097/IPC.0000000000001076
Ryom L, Boesecke C, Bracchi M. et al., 2018. Highlights of the 2017 European AIDS Clinical Society (EACS) guidelines for the treatment of adults with HIV, version 9.0. HIV Med. 19 (5), 309-315. https://doi.org/10.1111/hiv.12600.
Ryscavage P, Kelly S, Jonathan, P et al., 2014. Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy. 58(7), 3585-3598 https://doi.org/10.1128/AAC.00076-14.
UNAIDS Global AIDS Update. 2020. https://pancap.org/pc/pcc/media/pancap_document/2020_global-aids report_en.pdf
UNAIDS UNAIDS data 2022. https://www.who.int/en/news/item/23-07-2023-new-who-guidance-on-hiv-viral-suppression-and-scientific-updates-released-at-ias-2023 (accessed 05/07/2024 at 10:50 a.m.)
Vancoille L, Demecheleer E, Callens S et al., 2014. Markers associated with persistent low-level viremia under antiretroviral therapy in HIV-1 infection. J antimicrobial chemotherapy. 69(4): 1098-1103. https://doi.org/10.1093/jac/dkt484.
Vandenhende M A, Ingle S, May M et al., 2015. Impact of low-level viremia on clinical and virological outcomes in treated patients infected with HIV-1.AIDS. 29, 373-383. https://doi.org/10.1097/QAD.0000000000000544
WHO guidelines approved by the Guidelines Review Committee. Consolidated guidelines on the use of antiretroviral drugs to treat and prevent HIV infection: recommendations for a public health approach. Copyright © World Health Organization; Geneva. 2013.
WHO organization. World Health Organization; Geneva. Consolidated guidelines for strategic information on HIV in the health sector. WHO guidelines approved by the Guidelines Review Committee. 2015.
Wriden M, Todesco E, Valantin M A et al., 2015. Low-level HIV-1 viremia in patients on HAART, risk factors and management in clinical practice. J.antimicrobial chemotherapy. 70(8): 2347-2353. https://doi.org/10.1093/jac/dkv099
Yuan D, Zhou Y, Shi L et al., 2022. HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China. Front Public Health.14(10): 944-990. https://doi.org/10.3389/fpubh.2022.944990
Zhang T, Ding H, An M. et al., 2020. Factors associated with high-risk low-level viremia leading to virological failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis 20(1), 147. https://doi.org/10.1186/s12879-020-4837-y
Citations |
 |
 |
 |
 |
